Tirzepatide 15mg

Tirzepatide 15mg — higher-dose format for extended or multi-dose research protocols. Same dual GLP-1/GIP mechanism with ~5-day half-life and once-weekly dosing in animal models.

• Dual receptor activation — simultaneous GLP-1 and GIP agonism for synergistic metabolic effects.
• Superior weight-reduction profile — Phase 3 SURMOUNT data: up to −22.5% mean body weight reduction.
• Improved insulin sensitivity — GIP receptor pathways in adipocytes and skeletal muscle.
• Long-acting pharmacokinetics — ~5-day plasma half-life.

⚠️ For research use only. Not for human or animal consumption. Store lyophilised powder at −20°C. Reconstitute with Bacteriostatic Water.